Symbiosis Pharmaceutical Services has announced the FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK.  Symbiosis recently hosted a successful inspection by the United States Government Food and Drug Administration (FDA) for the aseptic manufacture of viral vector products for commercial supply into the U.S market at its GMP manufacturing facility, which has been licensed by the United Kingdom governments’ regul...